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P-glycoprotein inhibitors stimulate renal phosphate reabsorption mainly reabsorbed in the proximal tubule through the
in rats. type 2 sodium-phosphate cotransporter (NPT2). This
Background. Dipyridamole (Dip) was previously shown to transporter is exclusively detected in the brush border ofincrease renal phosphate (Pi) reabsorption in humans. How-
proximal tubular cells [3] and transports approximatelyever, the mechanism(s) underlying this renal tubular effect is
80% of the Pi reabsorbed in the kidney [4]. In vivo,not fully elucidated. It is known that Dip inhibits the activity
of the P-glycoprotein (Pgp) multidrug resistance protein 1 hormonal modulation of renal Pi reabsorption [for exam-
(MDR1) expressed on the apical membrane of renal proximal ple, by parathyroid hormone (PTH) or dopamine] has
tubular cells where the Na-Pi cotransporter (NPT2) is also been ascribed to changes in activity and/or expressionexpressed. We hypothesized that Dip could increase renal Pi
of NPT2. In pathology, NPT2 expression is decreased inreabsorption by inhibiting Pgp activity.
mice and probably in humans, with X-linked hypophos-Methods. To test this hypothesis, the effects of Dip, vera-
pamil (Ver), and cyclosporine A (CsA), three unrelated Pgp phatemia due to mutations in the PHEX gene [5, 6].
inhibitors, were studied on the renal Pi reabsorption in rats. An impairment of renal reabsorption of Pi leads to
Results. All three drugs decreased the fractional excretion
hypophosphatemia with high urinary Pi excretion thatof Pi (FEPi) in a dose-dependent manner within one hour after
may induce bone demineralization, hypervitaminosis D,beginning the drug infusion, without altering the glomerular
filtration rate or serum parathyroid hormone concentration. hypercalciuria, and urolithiasis [4, 7–11]. We have recently
Sodium-dependent Pi uptake but not Na-glucose transport was shown that dipyridamole (Dip) increases renal Pi reab-
increased in brush-border membrane vesicles (BBMVs) when sorption and serum phosphorus in patients with hypo-
comparing treated with untreated rats. Western blot analysis
phosphatemia resulting from idiopathic renal Pi leakshowed that NPT2 protein was increased in BBMVs from
[12]. The mechanism whereby Dip stimulates renal Pitreated rats. Dip and Ver had no effect when applied directly
to BBMVs prepared from untreated rats. Pretreatment of rats reabsorption in vivo is not fully understood. This drug
with colchicine prevented the effects of Dip on the FEPi and has multiple pharmacological properties and cellular tar-
NPT2 expression in brush-border membranes. gets. Particularly, Dip inhibits cellular adenosine uptakeConclusions. Our results suggest that inhibition of Pgp in the
[13, 14] and P-glycoprotein (Pgp) activity [15]. The Pgpsproximal tubule increases Pi uptake and NPT2 translocation to
are encoded by the multidrug resistance genes. One ofthe apical membrane.
these proteins, multidrug resistance protein 1 (MDR1)
Pgp, is expressed in the apical membrane of renal proxi-
mal tubular cells [16]. It is a 170 kD protein belongingPhosphate (Pi), one of the most abundant anions in
to the ATP binding cassette (ABC) superfamily, whichhumans, plays a central role in cellular metabolism and
bone mineralization. Pi homeostasis is controlled by the can extrude a wide variety of hydrophobic amphipathic
kidney, which adapts urinary Pi excretion to Pi uptake compounds from proximal cells to urine [17, 18]. The
in order to keep serum Pi in a normal range [1, 2]. Pi is members of the ABC family are thought to be regulatory
agents. Hence, MDR1 Pgp has been shown to activate
a chloride channel [19]. Since on the one hand Na-Pi
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sured in proximal tubule in vivo, the stimulation of Pi Na-dependent transport measurements
reabsorption and inhibition of MDR Pgp activity in- The uptakes of Pi and -methyl glucopyranoside were
duced by Dip cannot be directly correlated. To circum- performed on freshly isolated BBMVs. Uptakes were
vent this problem, we compared the effects of Dip and performed in a buffered solution containing (mmol/L)
two other inhibitors of MDR1 Pgp activity [verapamil 150 NaCl, 16 HEPES-Tris (pH 7.5). Na-free solutions
(Ver), cyclosporine A (CsA)] on renal Pi reabsorption were made iso-osmotic by replacing NaCl with mannitol
in rats. We measured urinary Pi excretion in vivo and 300 mmol/L. The BBMVs were incubated for five seconds
NPT2 expression in brush-border membranes from prox- in the presence of 0.1 mmol/L KH2PO4 mixed with [32P]
imal tubules. This study shows that all three Pgp inhibi- orthophosphate (0.5 Ci/mL) or of 1 mmol/L -methyl
tors increased renal Pi reabsorption through increased glucopyranoside mixed with [14C] -methyl glucopyrano-
expression of NPT2 in brush-border membranes, sug- side (1Ci/mL). The uptake was stopped by the addition
gesting that Pgp modulates renal Pi transport. of 1 mL of ice-cold solution consisting of (mmol/L) 300
mannitol, 10 HEPES-Tris (pH 7.5), 2 CaCl2, and 10 Na
arsenate. The BBMV suspensions were then applied toMETHODS
0.45m size pore filters under vacuum conditions. Filters
Experimental animals, clearance studies
were washed twice with 3 mL of ice-cold stop solution and
Experiments were performed with four- to six-week- processed for liquid scintillation counting. Na-dependent
old male Sprague-Dawley rats. The animals were fed a uptakes were calculated by subtracting uptake values
0.6% Pi diet. Tritiated inulin clearance studies were car- measured in Na-free solutions from those obtained in
ried out on anesthetized animals as previously described the presence of Na. Protein concentrations were mea-
[20]. Inulin clearance measurements were made twice dur- sured by the method of Bradford [23]. Uptake values were
ing periods without drugs (basal periods) and after drug corrected for protein content.
infusion (experimental periods). Dip was from Boeh-
Western blotringer Ingelheim France (Paris, France). Ver was from
Laboratoire Knoll (Levallois Perret, France), and CsA Aliquots of BBMV were denaturated for five minutes
was from Sigma Chemical Co. (St. Louis, MO, USA). All at 95C in 2% sodium dodecyl sulfate (SDS), 10% glyc-
drugs were diluted in isotonic saline and, after the control erol, 0.5 mmol/L ethylenediaminetetraacetic acid (EDTA),
periods, infused throughout the duration of experiments. and 95 mmol/L Tris-HCl, pH 6.8. Ten micrograms of
Dip was infused at a maximal rate of 25 g/min/100 g BBMV proteins were loaded per lane and separated
body weight, Ver at 7.5 g/min/100 g body weight, and on 10% polyacrylamide gel according to the method of
CsA at 50 g/min/100 g body weight. In a set of experi- Laemmli [24] and electrotransferred on nitrocellulose
ments, rats were treated with colchicine (100 g/100 g membranes. After blockage with 5% fat-free milk powder
body weight), dissolved in isotonic saline, and adminis- and 1% Triton X-100 in Tris-buffered saline (20 mmol/L,
tered via intraperitoneal injection three hours before pH 7.3), the membranes were incubated with the primary
Dip infusion. This dose of colchicine has been shown to antibody against NPT2 [24] or -actin (Sigma Immuno-
disrupt the microtubule network [21]. Serum and urinary chemical Co.) at a final dilution of 1:5000 and 1:10,000,
phosphorus concentrations were determined using a respectively. The primary antibody binding was visual-
standard method (Phosphore UV; Merck Clevenot, ized by chemiluminescence using the ECL Western blot-
Cheneviere les Louvres, France). Serum PTH concentra- ting detection system (Amersham, les Ulis, France).
tion determination was made with an immunoradiome- Quantification was made using the NIH imager version
tric kit assay (Nichols Institute Diagnostics, Immutopics 1.6 software (Bethesda, MD, USA).
Inc., San Clemente, CA, USA).
Statistical analysis
Preparation of brush-border membrane vesicles Fractional excretion of Pi (FEPi) values were compared
At the end of the experiments, blood was drawn from using an analysis of variance (ANOVA) for repeated
the aorta, and the kidneys were rapidly removed. Thin measures followed by a PLSD Fisher’s test. Other com-
slices of cortex were cut at 4C and homogenized with parisons were made using a two-way ANOVA and a
a Polytron in a buffer consisting of (mmol/L): 300 DL- PLSD Fisher’s test when allowed by F values. Results
mannitol, 5 egtazic acid (EGTA), 0.5 phenylmethylsulfo- are presented as mean  SE.
nyl fluoride, and 16 HEPES (pH 7.5 adjusted with Tris).
Brush-border membrane vesicles (BBMVs) were ob-
RESULTStained from this homogenate by Mg2 precipitation as
Effects of Pgp inhibitors on glomerular filtration ratedescribed by Levi, Jameson, and Van der Meer [22]. The
final pellet was resuspended in a buffer consisting of 300 Because renal Pi excretion can be affected by variations
of glomerular filtration rate (GFR), we first determinedmmol/L mannitol and 16 mmol/L HEPES-Tris, pH 7.5.
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Table 1. Effect of dipyridamole (Dip), verapamil (Ver) or cyclosporine A (CsA) on glomerular filtration rate (GFR)
GFR
P values
Basal periods Experimental periods experimental vs. basal
Control 1.400.04 1.450.06 NS
Dip 18 g/min/100 g 1.470.02 1.430.05 NS
Dip 25 g/min/100 g 1.360.05 1.390.09 NS
Ver 5 g/min/100 g 1.480.04 1.310.08 NS
Ver 7.5 g/min/100 g 1.330.05 1.260.09 NS
CsA 30 g/min/100 g 1.460.07 1.60.02 NS
CsA 50 g/min/100 g 1.520.16 1.400.15 NS
GFR was measured before (basal) and after (experimental) infusion of different doses of drugs or vehicle alone (control). GFR is expressed as mL/min. The
drugs did not modify GFR. NS is not significant.
Fig. 1. Effects of dipyridamole, verapamil, and
cyclosporine A on fractional excretion of phos-
phate in rats. Rats were infused with vehicle
alone (control), dipyridamole (18 or 25 g/min/
100 g), verapamil (5 or 7.5 g/100 g/min), or
cyclosporine A (30 or 50 g/min/100 g), as
described in the Methods section. Fraction-
ated excretion of phosphate was measured be-
fore (basal: B) and after (experimental: E)
infusion of drugs. Dipyridamole, verapamil,
and cyclosporine significantly decreased frac-
tionated excretion of phosphate. There was no
difference between drugs. *P  0.05; ***P 
0.001 compared with basal values (N  10).
the maximal doses of Dip, Ver, and CsA that could be not significantly different between the drugs and ranged
from 51 (25 g/min/100 g body weight of Dip) to 66%infused to rats without altering GFR. GFR was assessed
during basal periods and after infusion of the drugs or (50 g/min/100 g body weight of CsA). As shown in
Figure 2, the decrease of FEPi induced by the three drugsthe vehicle alone (control). GFR remained unchanged
for infusion rates up to 25 g/min/100 g body weight, occurred within one hour after beginning the drug infu-
sion and was maximal after 90 minutes. The kinetic of7.5 g/min/100 g body weight, and 50 g/min/100 g body
weight for Dip, Ver, and CsA, respectively (Table 1). inhibition was similar for the three drugs (Fig. 2). Serum
phosphorus was slightly but not significantly increasedThese infusion rates (Dip, 25 g/min/100 g body weight;
Ver, 7.5 g/min/100 g body weight; CsA, 50 g/min/100 by drug infusion (Table 2).
g body weight) were used for all subsequent experiments
Lack of modification of serum PTH concentrationsexcept for the study of the dose effect of the drug on
FEPi (discussed later in this article). In vivo, a major determinant of FEPi is the serum PTH
level. We measured serum PTH values after infusion of
Effects of Pgp inhibitors on fractional excretion of Pi Dip, Ver, or vehicle alone (control). Drug infusion did not
modify serum PTH concentrations when compared withFirst, the effects of Dip, Ver, and CsA infusion on the
FEPi were studied. FEPi was measured before (basal) and control (serum PTH in controls, 23.7  1.5; Dip, 24.3 
3.3; and Ver, 24.0  4.2 pg/mL; mean  SEM, N  3).after (experimental) infusion of the drug or the vehicle.
Figure 1 shows that basal values of FEPi were similar in
Effect of Pgp inhibitors on phosphatethe four groups of rats. However, after the drug treat-
and glucose uptakement, FEPi significantly decreased in all groups except
in controls (Fig. 1). The effect of Dip, Ver, and CsA on The first and limiting step of Pi reabsorption in the
proximal tubule is the transport through apical mem-FEPi was dose dependent, as shown in Figure 1. At the
maximal infusion rates used, the decrease of FEPi was branes where Na-Pi cotransporters are expressed. To eval-
Prie´ et al: Pgp inhibitors increase Pi reabsorption1072




Dipyridamole 25 lg/min/100 g 2.510.1 2.690.08
Verapamil 7.5 lg/min/100 g 2.490.11 2.660.12
Serum phosphorus was determined before and two hours after beginning the
drug infusion. The differences did not reach significance (ANOVA for repeated
measures). The results are expressed as the mean  SE, N  7.
increase in Na-dependent uptake demonstrated in BBMV
prepared from Pgp inhibitor-treated rat kidneys was as-
sociated with an increase in NPT2 expression, Western
blotting was used to compare the NPT2 protein abun-
dance in BBMVs from control rats and rats treated by
Dip, Ver, or CsA. The drug infusion led to a 50% in-
crease of NPT2 protein in BBMV with no difference
between drugs (Fig. 4); however, NPT2 protein abun-
dance in cortical homogenate was not modified by Dip
treatment (Fig. 5).
The effects of these drugs on NPT2 protein expression
were compared to those observed after an acute suppres-
Fig. 2. Time effects of P-glycoprotein (PgP) inhibitors on fractionated sion of PTH secretion by parathyroidectomy. Under
excretion of phosphate. Time 0 indicates the beginning of drug infusion. these conditions, urinary Pi excretion became undetect-
Drugs were infused over one hour. At the end of infusion, FEPi had able within 30 minutes. Two hours after parathyroidec-significantly decreased for the three drugs, and the curves reached a
plateau within 90 minutes, which was maintained for up to 120 minutes tomy, the kidneys were removed, and BBMVs were pre-
(N  10). Symbols and infusion rates of drugs are: () dipyridamole pared to measure NPT2 expression by Western blotting.
25 g/min/100 g; () verapamil 7.5 g/min/100 g; () cyclosporine 50
In parathyroidectomized rats, NPT2 expression was in-g/min/100 g.
creased by 84% by comparison with sham-operated rats
(data not shown).
uate whether the increase of Pi reabsorption was due to
Consequences of colchicine treatment on Dip effectsa primary modification of the apical transport, Pi uptake
was measured in BBMVs prepared from rats treated To determine whether the increase in NPT2 expres-
either by Dip, Ver, or vehicle alone. Sodium-dependent Pi sion evidenced in Pgp inhibitor-treated rats was depen-
uptake was significantly higher (40% increase) in BBMVs dent on the integrity of the microtubule network, the
from rats treated by Pgp inhibitors as compared with con- influence of colchicine on the antiphosphaturic effect of
trols, while sodium-independent Pi uptake was not sig- Dip was evaluated at doses known to disrupt the microtu-
nificantly altered by drug treatment (Table 3). We also bule network in the kidney [21]. Colchicine pretreatment
measured BBMV Na-dependent -methylglucopyrano- of the rats prevented the decrease of FEPi induced by
side uptake. The results showed that neither the Dip nor Dip (Fig. 6). In addition, NPT2 protein expression in
Ver treatment modified glucose uptake (Table 3), indi- BBM from Dip  colchicine-treated rat was lower than
cating that the drugs specifically stimulated Pi transport. that measured in rat treated with Dip alone (Fig. 7).
To determine whether the effect of Pgp inhibitors on
Pi uptake resulted from a direct interaction between
DISCUSSIONthese drugs and Na-Pi cotransporters, Dip, or Ver were
This work shows that three dissimilar and well-knownadded in vitro to BBMV obtained from untreated rats
inhibitors of Pgp activity—Dip, Ver, and CsA—decreased(Fig. 3). Under these conditions, Na-dependent Pi up-
renal FEPi and increased Na-dependent Pi transport intake was not modified, suggesting that the drugs could
BBMV and NPT2 expression in the apical membrane ofnot alter the activity of the Pi transporters directly.
proximal tubular cells.
Effect of Pgp inhibitors on NPT2 abundance Parathyroid hormone is known to inhibit Pi reabsorp-
and distribution tion by the renal proximal tubule. However, PTH did
not mediate any drug effect on Pi reabsorption, sinceApproximately 80% of Pi is reabsorbed in the proxi-
mal tubule through the NPT2. To determine whether the the serum PTH concentration was not modified follow-
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Table 3. Phosphate (Pi) and glucose uptake in brush-border membrane vesicles (BBMV) from rats treated by dipyridamole
(25 g/min/100 g), verapamil (7.5 g/min/100 g) or saline solution (control)
Na-dependent Pi uptake Na-independent Pi uptake Na-dependent glucose uptake
pmol Pi/5 s/mg protein pmol Pi/5 s/mg protein nmol glucose/5 s/mg protein
Control 407.59.7 115.817.1 433.666
Dipyridamole 563.829.7a 125.811.8 436.158.1
Verapamil 560.012.1a 126.06.8 435.7109.7
N  4. Pgp inhibitors increased Na-dependent Pi uptake but did not modify Na-dependent glucose transport. Na-independent Pi uptake was not modified by the
dipyridamole or verapamil treatment.
aP  0.005, ANOVA and PLSD Fisher’s test
Fig. 3. Effect of drugs directly added to brush-border membrane vesi-
cles (BBMV). BBMVs from untreated rats were incubated with vehicle
alone (control), dipyridamole (80 mol/L), or verapamil (0.1 mol/L)
for 30 minutes, and then Na-dependent Pi uptake was measured. Pi
uptake was not modified by PgP inhibitors in this experimental condition
(N  4).
ing drug infusion. These results are in agreement with
our previous study in humans in which Dip increased
Fig. 4. Type 2 sodium-phosphate transporter (NPT2) protein expres-renal Pi reabsorption and serum phosphorus in patients
sion in BBMV from rats treated by vehicle (control) or by dipyridamole
with hypophosphatemia and renal Pi leak with no change (25 g/min/100 g), verapamil (7.5 g/min/100 g), or cyclosporine (50
g/min/100 g). BBMVs were prepared as described in the Methodsin serum PTH concentration [12]. Furthermore, that
section. NPT2 was detected using a specific antibody. (A) Representa-study demonstrated that Dip treatment did not modify
tive Western blot in BBMVs from different rats. (B) Results of the
urinary cAMP values [12], suggesting that the effect of different experiments are expressed as arbitrary OD units, normalized
for  actin density. NPT2 protein abundance was significantly higherDip on FEPi was not due to a modification of cAMP
in rats treated by Pgp inhibitors. ***P  0.001 (N  4).synthesis by the proximal tubule.
The increase of Pi transport in vivo following drug infu-
sion cannot be attributed to a decrease in intracellular Na
concentration, which would stimulate the Na-dependent from other calcium-channel blockers by its capacity to
processes, because (1) it persisted in BBMV in which the inhibit MDR1 Pgp activity [25]. Few studies describe the
gradient of Na is imposed and (2) these drugs did not effect of calcium-channel blockers on renal Pi excretion.
affect Na-dependent glucose uptake. Lupinacci et al examined the effects of nitrendipine on
Verapamil’s effect on renal Pi reabsorption is similar FEPi in normal and hypertensive subjects and found that
this drug, which does not inhibit Pgp activity, increasedto Dip. Ver is a calcium-channel blocker that differs
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Fig. 6. Pretreatment of rats by colchicine prevents the decrease in FEPi
following dipyridamole infusion (25 g/min/100 g). Rats were treated
by colchicine (0.1 mg/100 g body weight) intraperitoneally three hoursFig. 5. NPT2 protein abundance in renal cortical homogenates from
rats treated by vehicle (control) or dipyridamole (25 g/min/100 g). before dipyridamole infusion. FEPi was compared before (B) and after
dipyridamole infusion (E) in each rat. Dipyridamole infused alone(A) Representative Western blot in renal cortical homogenates from
different rats. (B) Results of the different experiments (N  4) are decreased FEPi, and colchicine treatment abolished the effects of dipyri-
damole on FEPi.expressed as arbitrary OD units, normalized for  actin density. NPT2
protein expression was not significantly different in controls and dipyri-
damole-treated rats.
ment [31] probably by preventing Na,K-ATPase dephos-
phorylation. The expected consequence of a diminishedFEPi [26]. These results suggest that the calcium-channel
Na,K-ATPase activity is the decrease of the Na-depen-blocker properties cannot explain the Ver-induced de-
dent uptakes. In the current study, renal Pi reabsorptioncrease of FEPi. Two reports describe an effect of Ver on
was increased but the glucose uptake was not modified.renal Pi reabsorption. In a clinical study, Sjo¨den et al
These findings indicate that the effect of CsA cannotfound that Ver significantly increased serum phosphorus
be attributed to an inhibition of Na,K-ATPase activity.in patients with postsurgical hypoparathyroidism [27].
Furthermore, an increase in Pgp expression [33] and aThe authors did not measure the tubular transport maxi-
specific decrease in Pi uptake in renal BBMV [34] havemum of Pi (TmPi), but this value can be estimated from
been demonstrated following several days of CsA treat-the data given in the article. Using two methods, the
ment in the rats. These results suggest that Pgp maynomogram of Walton and Bijvoet [28] and the equation
modulate renal Pi uptake. In humans, Palestine, Austin,defined by Kenny and Glen [29], the average value of
and Nussenblatt measured the renal Pi threshold (TmPi)TmPi was higher in patients treated with Ver.
in patients treated with CsA during 180 days for immuneIn the opossum kidney epithelial cell line, Abraham,
uveitis and found no significant change in TmPi [35].McAteer, and Kempson showed that in the presence of
However the authors did not study the short-term effectsinsulin, Ver increased Pi uptake [30].
of CsA on TmPi, that is, before inducing Pgp expression.Cyclosporine A is an immunosuppressive drug and a
Thus, although each compound has specific propertiescompetitive inhibitor of MDR1 Pgp that reproduces the
in addition to its ability to inhibit PgP activity, the dataeffect of Dip on FEPi. In the cytoplasm, CsA binds to
from our present study and the literature all support thecyclophilin. The CsA-cyclophilin complex binds to the
conclusion that the effects of the compounds on FEPi are subunit of calcineurin, preventing calcineurin-phos-
associated with their capacity to inhibit PgP.phatase activity from being induced by an increase in
The Dip-, Ver-, and CsA-induced decrease in FEPicytosolic Ca [31, 32]. Calcineurin activity is present in
(Fig. 1) was associated with a specific increase in Na-the proximal tubule [31], and at high concentrations,
CsA inhibits Na,K-ATPase activity in this tubular seg- dependent Pi uptake in BBMV (Table 3) and in NPT2
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that an intact microtubule network was mandatory for
Dip to have an effect. These results suggest that Dip,
and most likely Ver and CsA, decrease FEPi by stimulat-
ing NPT2 translocation in BBM.
We could not correlate the inhibition of Pgp activity
to an increase in renal Pi reabsorption because, to our
knowledge, there is no reliable method for measuring
Pgp activity in the kidney in vivo or in BBMV. Pgp
activity can be measured in proximal tubular cells in
culture, but NPT2 expression rapidly decreases in these
cells, thus precluding all conclusions.
In conclusion, we have shown three unrelated drugs
that are known to inhibit Pgp activity, augmented renal
Pi reabsorption in rats by increasing NPT2 expression
in the apical membrane of proximal tubular cells. These
findings may explain the effect of Dip on renal Pi thresh-
old in humans, and lead to new insights into renal Pi
transport regulation and treatment of renal Pi leak.
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Fig. 7. Pretreatment of rats by colchicine prevents the increase of NPT2
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